Disease area

Obesity trial monitoring.

Public-record monitoring of obesity and cardiometabolic programs — GLP-1, GIP, amylin, glucagon, oral and injectable combination therapies — across registry, FDA, sponsor disclosure, and literature sources.

Search obesity See pricing

Why obesity

The obesity pipeline has expanded rapidly. Phase 3 read-out timing on GLP-1 and combination programs shifts competitor positioning, payer modeling, and label-expansion narratives across cardiometabolic indications. Movement on a lead Phase 3 — a primary-completion shift, a supply-related amendment, an FDA correspondence reference in an 8-K — is meaningful and public.

What Clinical Trial Signal monitors in obesity

GLP-1 and incretin programs

Active programs by sponsor, mechanism, route, and combination.

Phase 3 read-out timing

Primary-completion-date shifts and status changes on lead programs.

Indication expansions

Cardiometabolic indication expansions — heart failure, MASH, CKD, OSA, and others.

Supply and recall signal

openFDA enforcement records relevant to marketed obesity therapeutics.

Sponsor 8-K disclosures

Sponsor-disclosed obesity read-outs, partnerships, capacity, and FDA correspondence references.

Literature

Major endocrinology and cardiometabolic publications.

Who uses obesity monitoring

Analysts

Competitive read on incretin landscape

Watch competing GLP-1, GIP, and combination programs.

Consultants

Obesity client briefs

Source-backed briefs anchored to primary records.

Small biotech & BD

Counterparty pipeline read

Read counterparty pipeline disclosures before partnership conversations.

Journalists

Material obesity events

Status reversals, read-outs, supply events.

Source caveats

Registry data is self-reported. Date moves do not establish cause. Sponsor 8-K references to FDA correspondence are sponsor statements. This is not medical advice, not regulatory advice, and not investment advice.

Start tracking obesity

See pricing Search obesity free

Compliance-safe positioning. Clinical Trial Signal provides public-data research intelligence. It is not medical advice, legal advice, regulatory advice, investment advice, or a pharmacovigilance system of record.